Michael Lock

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial

David A. Palma, Robert Olson, Stephen Harrow et al. · The Lancet · 2019 · 1.8K citations

Open-label Trial, Radiation Therapy, Medicine +7

Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial

David A. Palma, Robert Olson, Stephen Harrow et al. · Journal of Clinical Oncology · 2020 · 1.2K citations · Full text

External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial

Timothy J. Whelan, Jim A. Julian, Tanya Berrang et al. · The Lancet · 2019 · 407 citations

Surgical Oncology, Breast Oncology, Radiation Therapy +11

Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer

Jeff M. Michalski, Jennifer Moughan, James A. Purdy et al. · JAMA Oncology · 2018 · 346 citations · Full text

Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial

David A. Palma, Cornelis J.A. Haasbeek, George Rodrigues et al. · BMC Cancer · 2012 · 306 citations · Full text